Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) Director Cyrus Harmon sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $10.93, for a total value of $54,650.00. Following the completion of the transaction, the director now owns 786,283 shares […]
Cantor Fitzgerald reaffirmed their overweight rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. Several other equities analysts also recently issued reports on ORIC. JPMorgan Chase & Co. reduced their price objective on ORIC Pharmaceuticals from $19.00 to $18.00 and set an […]
HC Wainwright reissued their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY – Free Report) in a report issued on Wednesday, Benzinga reports. The brokerage currently has a $4.50 price objective on the stock. Several other brokerages have also recently commented on UNCY. Noble Financial started coverage on Unicycive Therapeutics in a research report on […]
Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM – Get Free Report) have earned an average rating of “Buy” from the four brokerages that are covering the stock, Marketbeat reports. Four analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have covered the stock in the last year […]
Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) was the target of a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 2,450,000 shares, a decrease of 21.2% from the April 30th total of 3,110,000 shares. Approximately 16.0% of the shares of the stock are […]